Phase 1 Head and Neck Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 19 years or older
- People who have been diagnosed with squamous cell carcinoma (a type of cancer) of the head and neck, confirmed by a biopsy, where the lymph nodes either show no signs of cancer or are considered suspicious
- People with any stage of head and neck cancer, at any location within the head and neck area, who are already scheduled for surgery to remove the tumour — including those whose cancer has come back or who have developed a new cancer
- People who are already planned to have a standard neck dissection (surgery to remove lymph nodes in the neck) as part of their care
- People whose blood test results meet certain health thresholds, including healthy enough levels of red blood cells, white blood cells, platelets, and kidney function markers (confirm specific values with the trial site)
Who may not be able to join:
- People who have had a heart attack, stroke, uncontrolled heart failure, significant liver disease, or unstable chest pain within the 6 months before joining the trial
- People who have previously had a serious reaction to a type of medication called a monoclonal antibody given by infusion
- People with a known allergy to iodine
- People who are pregnant or breastfeeding
- People whose magnesium or potassium blood levels are below the normal range used by the treating hospital
- People taking certain heart rhythm medications, specifically Class IA drugs (such as quinidine or procainamide) or Class III drugs (such as dofetilide, amiodarone, or sotalol)
- People with a history or signs of lung inflammation or scarring of the lungs (conditions known as interstitial pneumonitis or pulmonary fibrosis)
- People with severe kidney disease or a complete absence of urine production
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Eben Rosenthal, MD, Vanderbilt University/Ingram Cancer Center
Phone: 615-936-2807
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of adverse events grade 2 or higher
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.